Free Trial

Valneva SE (NASDAQ:VALN) Short Interest Down 56.3% in May

Valneva logo with Medical background

Valneva SE (NASDAQ:VALN - Get Free Report) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 2,100 shares, a drop of 56.3% from the May 15th total of 4,800 shares. Currently, 0.0% of the company's shares are short sold. Based on an average daily trading volume, of 74,200 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On Valneva

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC acquired a new position in Valneva in the 1st quarter valued at $94,000. ABC Arbitrage SA bought a new position in shares of Valneva in the fourth quarter worth about $84,000. Finally, Wells Fargo & Company MN lifted its position in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after purchasing an additional 30,859 shares during the last quarter. Institutional investors own 11.39% of the company's stock.

Valneva Stock Down 3.1%

VALN traded down $0.19 on Tuesday, reaching $5.88. 23,279 shares of the company traded hands, compared to its average volume of 42,514. The company has a market cap of $500.35 million, a price-to-earnings ratio of -45.23 and a beta of 1.81. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock's 50 day moving average price is $6.46 and its 200-day moving average price is $5.97. Valneva has a 52-week low of $3.62 and a 52-week high of $8.66.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.27. The company had revenue of $51.79 million during the quarter, compared to the consensus estimate of $41.80 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. On average, sell-side analysts expect that Valneva will post 0.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on VALN shares. Guggenheim cut their price target on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Valneva in a report on Tuesday, April 15th.

Get Our Latest Report on Valneva

About Valneva

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

See Also

Should You Invest $1,000 in Valneva Right Now?

Before you consider Valneva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.

While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines